https://scholars.lib.ntu.edu.tw/handle/123456789/465320
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Tu T.-Y | en_US |
dc.contributor.author | Yang S.-J | en_US |
dc.contributor.author | Tsai M.-H | en_US |
dc.contributor.author | Wang C.-H | en_US |
dc.contributor.author | Lee S.-Y | en_US |
dc.contributor.author | Tai-Horng Young | en_US |
dc.contributor.author | MING-JIUM SHIEH | en_US |
dc.creator | Tu T.-Y;Yang S.-J;Tsai M.-H;Wang C.-H;Lee S.-Y;Tai-Horng Young;Shieh M.-J. | - |
dc.date.accessioned | 2020-02-27T03:57:00Z | - |
dc.date.available | 2020-02-27T03:57:00Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0927-7765 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/465320 | - |
dc.description.abstract | Cancer is a complex and tenacious disease. Drug-delivery systems in combination with multimodal therapy strategies are very promising candidates for cancer theranostic applications. In this study, a new drug-delivery vehicle that combine human serum albumin (HSA)- and poly(sodium 4-styrenesulfonate) (PSS)-coated gold nanorod nanoparticles(GNR/PSS/HSA NPs) was developed for synergistic cancer therapy. Doxorubicin (DOX) was loaded onto GNR/PSS/HSA NPs, by electrostatic and hydrophobic forces, to create multimodal DOX@GNR/PSS/HSA NPs. DOX@GNR/PSS/HSA NPs were found to be highly biocompatible and stable in physiological solutions. Furthermore, GNR/PSS/HSA NPs with or without DOX were designed to exhibit strong absorbance in the near-infrared region and high photothermal conversion efficiency. Therefore, bimodal DOX release from DOX@GNR/PSS/HSA NPs could be triggered by an acidic pH and by near-infrared irradiation after NPs preferentially accumulated at tumor sites, leading to a significant chemotherapeutic effect. Moreover, DOX@GNR/PSS/HSA NPs were designed to be applied during chemo- and photo-thermal combination therapy and exhibited a synergistic anticancer effect that was superior to the effect of monotherapy, from both in vitro and in vivo results. These results suggest that DOX@GNR/PSS/HSA NPs are a strong candidate for a nanoplatform for future antitumor therapeutic strategies. ? 2018 | - |
dc.relation.ispartof | Colloids and Surfaces B: Biointerfaces | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | Biocompatibility; Body fluids; Chemotherapy; Diseases; Drug products; Gold coatings; Gold nanoparticles; Infrared devices; Nanoribbons; Nanorods; Oncology; Targeted drug delivery; Controlled drug release; Gold nanorod; Human serum albumins; Photothermal conversion efficiencies; Photothermal therapy; Physiological solution; Polysodium 4-styrenesulfonate; Triggered drug release; Controlled drug delivery; doxorubicin; gold nanorod; human serum albumin; polystyrenesulfonate sodium; antineoplastic antibiotic; doxorubicin; gold; human serum albumin; nanotube; polymer; styrenesulfonic acid polymer; sulfonic acid derivative; adsorption; animal experiment; animal model; antineoplastic activity; aqueous solution; Article; body weight loss; cancer chemotherapy; cancer inhibition; cell viability; coated particle; concentration response; controlled drug release; controlled study; drug cytotoxicity; drug delivery system; drug solubility; endosome; female; Fourier transform infrared spectroscopy; HeLa cell line; human; human cell; hydrophilicity; hydrophobicity; in vitro study; in vivo study; internalization; lysosome; mouse; nanopharmaceutics; nonhuman; particle size; pH; photothermal therapy; priority journal; static electricity; surface charge; temperature; tumor growth; tumor volume; uterine cervix cancer; zeta potential; animal; chemistry; delayed release formulation; drug formulation; drug release; drug screening; infrared radiation; low level laser therapy; metabolism; molecularly targeted therapy; multimodality cancer therapy; neoplasm; nude mouse; procedures; subcutaneous drug administration; Animals; Antibiotics, Antineoplastic; Combined Modality Therapy; Delayed-Action Preparations; Doxorubicin; Drug Compounding; Drug Liberation; Female; Gold; HeLa Cells; Humans; Hydrogen-Ion Concentration; Infrared Rays; Injections, Subcutaneous; Low-Level Light Therapy; Mice; Mice, Nude; Molecular Targeted Therapy; Nanotubes; Neoplasms; Polymers; Serum Albumin, Human; Sulfonic Acids; Xenograft Model Antitumor Assays | - |
dc.title | Dual-triggered drug-release vehicles for synergistic cancer therapy | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.colsurfb.2018.10.043 | - |
dc.identifier.pmid | 30384276 | - |
dc.identifier.scopus | 2-s2.0-85055677256 | - |
dc.relation.pages | 788-797 | - |
dc.relation.journalvolume | 173 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Biomedical Engineering | - |
crisitem.author.dept | Biomedical Engineering | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | School of Medicine | - |
crisitem.author.orcid | 0000-0001-5338-4747 | - |
crisitem.author.orcid | 0000-0003-2921-4443 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Engineering | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Engineering | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學工程學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。